Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer Publication of offer prospectus follows pre-announcement on July 20, 2026 Largest individual shareholder committed to tender all of its PolyPeptide shares into...
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion....